Cardiac Biomarkers Testing Market Report 2026

The cardiac biomarkers testing market size has grown rapidly in recent years. It will grow from $14.95 billion in 2025 to $16.7 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising incidence of cardiovascular diseases, increasing awareness about cardiac health, advancements in laboratory diagnostics, growing hospital infrastructure, increasing government healthcare initiatives.

The cardiac biomarkers testing market size is expected to see rapid growth in the next few years. It will grow to $25.92 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to adoption of AI in diagnostics, expansion of home-based and remote monitoring, growth of precision medicine, development of multi-biomarker panels, rising demand for real-time cardiac monitoring. Major trends in the forecast period include point-of-care testing adoption, miniaturized & portable diagnostic devices, biomarker multiplexing technologies, personalized cardiac risk profiling, integration of wearables for cardiac monitoring.

The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the cardiac biomarkers testing market in the coming years. Cardiovascular disease refers to conditions that affect the heart or blood vessels. Cardiac biomarker tests help measure biomarker levels to quickly assess the severity and extent of a heart attack. As a result, an increase in cardiovascular disease prevalence leads to higher demand for cardiac biomarker testing solutions. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, an increase of 4% from 224.4 per 100,000 in 2023. Therefore, the growing prevalence of cardiovascular diseases is driving the expansion of the cardiac biomarkers testing market.

Major companies operating in the cardiac biomarker testing market are adopting strategic partnerships to provide technology for detecting early warning signs of heart conditions and improving patient outcomes. Strategic partnerships in cardiac biomarker testing foster collaboration between companies, enabling the development of innovative diagnostics, expanding market reach, and accelerating the availability of advanced testing solutions for improved cardiovascular care. For instance, in September 2024, MediBuddy, an Indian-based healthcare technology company providing a comprehensive platform for telehealth services, health management, and insurance assistance, partnered with Philips, a Netherlands-based conglomerate corporation. With this partnership, they aim to enhance cardiac care in India by incorporating Philips' HeartPrint technology, enabling regular monitoring and risk assessment of heart health. This forward-thinking approach empowers users with advanced tools on the MediBuddy platform, fostering proactive management of heart health and better outcomes.

In July 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired LumiraDx’s point-of-care technology for an undisclosed amount. Through this acquisition, Roche aims to strengthen its diagnostics portfolio, particularly in decentralized and near-patient testing. By integrating LumiraDx’s innovative point-of-care platform, Roche seeks to enhance its ability to deliver rapid and accurate diagnostic results at or close to patient locations, supporting faster clinical decision-making. LumiraDx Ltd. is a UK-based healthcare company specializing in point-of-care diagnostic solutions, including cardiac biomarker testing such as the NT-proBNP assay.

Major companies operating in the cardiac biomarkers testing market are Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation.

North America was the largest region in the cardiac biomarkers testing market in 2025. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac biomarkers testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the cardiac biomarkers testing market by increasing the cost of imported diagnostic equipment, reagents, and consumables, causing delays in supply chains. The hospital and specialty clinic segments, particularly in Asia-Pacific and Europe, are most affected due to reliance on imported kits. While higher costs may temporarily slow adoption, tariffs are also encouraging local manufacturing and innovation in cost-effective cardiac testing solutions, potentially strengthening domestic capabilities and reducing long-term dependency on imports.

The cardiac biomarkers testing market research report is one of a series of new reports that provides cardiac biomarkers testing market statistics, including cardiac biomarkers testing industry global market size, regional shares, competitors with a cardiac biomarkers testing market share, detailed cardiac biomarkers testing market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac biomarkers testing industry. This cardiac biomarkers testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiac biomarker testing involves measuring the levels of specific cardiac biomarkers in the blood. It is used to diagnose, evaluate, and monitor individuals who may be experiencing acute coronary syndrome (ACS).

The primary biomarkers used in cardiac biomarker testing include creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), and others. Creatine kinase (CK-MB) is a blood test that detects a specific cardiac-related enzyme. These biomarkers are applied in conditions such as congestive heart failure, acute coronary syndrome, myocardial infarction, atherosclerosis, and others, with hospitals and specialty clinics serving as the main end users.

The cardiac biomarkers testing market includes revenues earned by entities by providing ischemia-modified albumin (IMA), peptides, and C-reactive protein (CRP) biomarkers testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.